AdventHealth Research Institute's Richard E. Pratley, MD, introduces the study rationale and design of the VERTIS CV Trial as part of the American Diabetes Association's 80th Scientific Sessions. 

Cardiovascular Outcomes Following Ertugliflozin Treatment in Patients with Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease 

Faculty

• Richard E. Pratley, MD, AdventHealth Research Institute, Orlando, FL USA
• Sam Dagogo-Jack, MD, DSc, University of Tennessee Health Science Center, Memphis, TN, USA
• Christopher P. Cannon, MD, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
• Darren K. McGuire, MD, MHSc, University of Texas Southwestern Medical Center, Dallas, TX, USA
• David Z.I. Cherney, MD, PhD, University of Toronto, Toronto, Ontario, Canada